https://orcid.org/0000-0002-7616-3872
References
- Amidon G, Lennernas H, Shah V, Crison J. 1995. A theoretical basis for a biopharmaceutic drug classification - the correlation of in-vitro drug product dissolution and in-vivo bioavailability. Pharm Res. 12(3):413–420.
- Andrés A, Rosés M, Ràfols C, Bosch E, Espinosa S, Segarra V, Huerta JM. 2015. Setup and validation of shake-flask procedures for the determination of partition coefficients (logD) from low drug amounts. Eur J Pharm Sci. 76:181–191.
- Banker MJ, Clark TH, Williams JA. 2003. Development and validation of a 96-well equilibrium dialysis apparatus for measuring plasma protein binding. J Pharm Sci. 92(5):967–974.
- Box KJ, Völgyi G, Baka E, Stuart M, Takács-Novák K, Comer JE. 2006. Equilibrium versus kinetic measurements of aqueous solubility, and the ability of compounds to supersaturate in solution–a validation study. J Pharm Sci. 95(6):1298–1307.
- Chan TS, Yu H, Moore A, Khetani SR, Tweedie D. 2019. Meeting the challenge of predicting hepatic clearance of compounds slowly metabolized by cytochrome P450 using a novel hepatocyte model, HepatoPac. Drug Metab Dispos. 47(1):58–66.
- Chi H, Li C, Zhao F, Zhang L, Ng T, Jin G, Sha O. 2017. Anti-tumor activity of toll-like receptor 7 agonists. Front Pharmacol. 8:304–310.
- Docci L, Parrott N, Krähenbühl S, Fowler S. 2019. Application of new cellular and microphysiological systems to drug metabolism optimization and their positioning respective to in silico tools. SLAS Discov. 24(5):523–536.
- Frega G, Wu Q, Le Naour J, Vacchelli E, Galluzzi L, Kroemer G, Kepp O. 2020. Trial Watch: experimental TLR7/TLR8 agonists for oncological indications. Oncoimmunology. 9(1):1796002–1796010.
- Khetani SR, Bhatia SN. 2008. Microscale culture of human liver cells for drug development. Nat Biotechnol. 26(1):120–126.
- Kratochwil NA, Meille C, Fowler S, Klammers F, Ekiciler A, Molitor B, Simon S, Walter I, McGinnis C, Walther J, et al. 2017. Metabolic profiling of human long-term liver models and hepatic clearance predictions from in vitro data using nonlinear mixed-effects modeling. Aaps J. 19(2):534–550.
- Miller NA, Reddy MB, Heikkinen AT, Lukacova V, Parrott N. 2019. Physiologically based pharmacokinetic modelling for first-in-human predictions: An updated model building strategy illustrated with challenging industry case studies. Clin Pharmacokinet. 58(6):727–746.
- National Research Council Committee for the Update of the Guide for the Care and Use of Laboratory. 2011. Guide for the care and use of laboratory animals. 8th ed. Washington (DC): National Academies Press.
- NCT04338685. 2020. A study evaluating safety, pharmacokinetics, pharmacodynamics, and clinical activity of RO7119929 (TLR7 Agonist) in participants with unresectable advanced or metastatic hepatocellular carcinoma, biliary tract cancer, or solid tumors with hepatic metastases; [accessed 2022 Jul 14]. https://clinicaltrials.gov/ct2/show/study/NCT04338685.
- Talukdar A, Ganguly D, Roy S, Das N, Sarkar D. 2021. Structural evolution and translational potential for agonists and antagonists of endosomal toll-like receptors. J Med Chem. 64(12):8010–8041.
- Umehara K, Cantrill C, Wittwer MB, Di Lenarda E, Klammers F, Ekiciler A, Parrott N, Fowler S, Ullah M. 2020. Application of the extended clearance classification system (ECCS) in drug discovery and development: selection of appropriate in vitro tools and clearance prediction. Drug Metab Dispos. 48(10):849–860.
- van der Sandt IC, Blom-Roosemalen MC, de Boer AG, Breimer DD. 2000. Specificity of doxorubicin versus rhodamine-123 in assessing P-glycoprotein functionality in the LLC-PK1, LLC-PK1:MDR1 and Caco-2 cell lines. Eur J Pharm Sci. 11(3):207–214.